Recombinant tissue plasminogen activator (TPA) fragments and uses thereof

EP4713445A2Pending Publication Date: 2026-03-25VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-05-17
Publication Date
2026-03-25

AI Technical Summary

Technical Problem

Current treatments for cardiovascular diseases, such as statins and PCSK9 inhibitors, only modestly reduce levels of atherogenic apoB-containing lipoproteins like VLDL, IDL, Lp(a), chylomicron, and chylomicron remnants, leaving residual cardiovascular risk in populations with controlled LDL cholesterol levels.

Method used

Development of recombinant tissue plasminogen activator kringle 2 domain (tPA-K2) fragments that bind to apolipoprotein B, inhibit its secretion, and disrupt lipidation, potentially lowering plasma levels of these lipoproteins, using nucleotide sequences encoding tPA-K2 polypeptides delivered via vectors like adeno-associated virus or lipid nanoparticles.

Benefits of technology

The tPA-K2 fragments effectively reduce plasma levels of atherogenic apoB lipoproteins, including VLDL, IDL, Lp(a), and chylomicron remnants, thereby lowering triglycerides and cholesterol, providing a new therapeutic approach for treating cardiovascular diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024029985_21112024_PF_FP_ABST
    Figure US2024029985_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present technology relates to recombinant polypeptides, or nucleotides encoding the same, comprising tissue plasminogen activator (tPA) fragments and uses thereof for treating cardiovascular diseases. In some embodiments, the tPA fragments comprise the kringle 2 domain of tPA.
Need to check novelty before this filing date? Find Prior Art